Endo Pharmaceuticals Holdings Inc (ENDP) 57.26 $ENDP
Endo Health Solutions Inc. Announces Receipt of Requisite Tenders and Consents in the Exchange Offers and Consent Solicitations Relating to its 7% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7A 1/4% Senior Notes due 2022
PR Newswire Europe - Thu Apr 17, 7:01AM CDT
Endo International plc ("Endo" or the "Company"
announced today that its wholly-owned subsidiary, Endo Health Solutions Inc. ("EHSI" , has received requisite tenders and consents in connection with its previously announced offers to exchange any and all of the outstanding unsecured 7% Senior Notes due 2019 (the "2019 Existing EHSI Notes" , 7.00% Senior Notes due 2020 (the "2020 Existing EHSI Notes" and 7A 1/4% Senior Notes due 2022 issued by EHSI (the "2022 Existing EHSI Notes" and, together with the 2019 Existing EHSI Notes and the 2020 Existing EHSI Notes, the "Existing EHSI Notes" , for new unsecured 7.00% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7.25% Senior Notes due 2022 (collectively, the "New Endo Finance Notes" , respectively, to be issued by Endo Finance LLC and Endo Finco Inc. and guaranteed by Endo Limited and certain of its direct and indirect subsidiaries, and the related solicitation of consents to amend the Existing EHSI Notes and the indentures governing the Existing EHSI Notes. Consents were solicited in respect of the indentures governing each series of the Existing EHSI Notes to approve proposed amendments that would, among other things, (i) delete in their entirety substantially all the restrictive covenants in each indenture, (ii) modify the covenants regarding mergers and consolidations, and (iii) eliminate certain events of default. Capitalized terms used but not defined herein shall have the meanings ascribed to them in EHSI's Offer to Exchange dated March 27, 2014 (as amended from time to time, the "Offer to Exchange" .
Endo Health Solutions Inc. Announces Receipt of Requisite Tenders and Consents in the Exchange Offers and Consent Solicitations Relating to its 7% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7¼% Senior Notes due 2022
PR Newswire - Thu Apr 17, 7:00AM CDT
Endo International plc (NASDAQ: ENDP) (TSX: ENL) ("Endo" or the "Company" announced today that its wholly-owned subsidiary, Endo Health Solutions Inc. ("EHSI" , has received requisite tenders and consents in connection with its previously announced offers to exchange any and all of the outstanding unsecured 7% Senior Notes due 2019 (the "2019 Existing EHSI Notes" , 7.00% Senior Notes due 2020 (the "2020 Existing EHSI Notes" and 7¼% Senior Notes due 2022 issued by EHSI (the "2022 Existing EHSI Notes" and, together with the 2019 Existing EHSI Notes and the 2020 Existing EHSI Notes, the "Existing EHSI Notes" , for new unsecured 7.00% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7.25% Senior Notes due 2022 (collectively, the "New Endo Finance Notes" , respectively, to be issued by Endo Finance LLC and Endo Finco Inc. and guaranteed by Endo Limited and certain of its direct and indirect subsidiaries, and the related solicitation of consents to amend the Existing EHSI Notes and the indentures governing the Existing EHSI Notes. Consents were solicited in respect of the indentures governing each series of the Existing EHSI Notes to approve proposed amendments that would, among other things, (i) delete in their entirety substantially all the restrictive covenants in each indenture, (ii) modify the covenants regarding mergers and consolidations, and (iii) eliminate certain events of default. Capitalized terms used but not defined herein shall have the meanings ascribed to them in EHSI's Offer to Exchange dated March 27, 2014 (as amended from time to time, the "Offer to Exchange" .
Noven Announces Settlement of Lidoderm(R) Patent Litigation
Business Wire - Wed Apr 16, 4:00PM CDT
Noven Pharmaceuticals, Inc. today announced that it has entered into an agreement with Endo Pharmaceuticals Inc., Teikoku Seiyaku Co., Ltd. and Teikoku Pharma USA, Inc. to settle all outstanding patent litigation related to Noven's lidocaine topical patch 5% product. An Abbreviated New Drug Application for Noven's product is currently pending at the U.S. Food and Drug Administration (FDA). If approved, Noven's product would be a generic version of Endo's Lidoderm(R).
Wednesday’s Top Health Care Stories: Zogenix, Endo, and Teva
Leo Sun, The Motley Fool - Motley Fool - Wed Apr 16, 8:21AM CDT
Let's take a quick look at three stocks -- Zogenix , Endo International , and Teva Pharmaceutical -- which could all loom large in health care headlines this morning. Zogenix surges after a U.S. court reverses the Massachusetts ban on...
Shares of ENDP Down 18.1% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Tue Apr 15, 5:04PM CDT
SmarTrend identified a Downtrend for Endo Pharmaceuticals (NASDAQ:ENDP) on March 24th, 2014 at $68.72. In approximately 3 weeks, Endo Pharmaceuticals has returned 18.10% as of today's recent price of $56.28.
Endo to Announce First Quarter 2014 Financial Results on May 1, 2014
PR Newswire Europe - Tue Apr 15, 3:01PM CDT
Endo International plc will announce its first quarter 2014 financial results before the open of the U.S. financial markets on May 1, 2014 and members of its senior management team will host a conference call and webcast at 7:30 a.m. ET that day.
Critical Alerts For Royal Dutch Shell, Keurig Green Mountain, Valspar, Lorillard, and Endo Pharmaceuticals Released By InvestorsObserver
PR Newswire - Tue Apr 15, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for RDS.A, GMCR, VAL, LO, and ENDP.
Legal Updates, Stock Price Movements, New Awareness Campaigns, and Senior-level Appointments - Analyst Notes on Mylan, WellPoint, Forest, Novatis and Intercept
PR Newswire - Tue Apr 15, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Mylan Inc. (NASDAQ: MYL), WellPoint Inc. (NYSE: WLP), Forest Laboratories Inc. (NYSE: FRX), Novatis AG (NYSE: NVS) and Intercept Pharmaceuticals Inc. (NASDAQ: ICPT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1162-100free.
Endo International (ENDP) Shares Cross Below 200 DMA
at The Street - Mon Apr 14, 3:42PM CDT
In trading on Monday, shares of Endo International plc Ord crossed below their 200 day moving average of $55.95, changing hands as low as $55.85 per share. Endo International plc Ord shares are currently trading off about 1% on the day.
Mylan to Settle with Endo on Frova - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 14, 10:40AM CDT
A federal district court granted Mylan's request to forge a settlement with Endo regarding Frova.
Mylan announces favourable settlement agreement with Endo Pharmaceuticals for Frovatriptan Succinate Tablets, 2.5 mg
M2 - Mon Apr 14, 9:05AM CDT
Pharmaceutical company Mylan (NasdaqGS:MYL) said on Friday that the federal district court has granted its request to enforce a settlement agreement with Endo Pharmaceuticals for Frovatriptan Succinate Tablets, 2.5 mg.
Endo Health Solutions Inc. Amends Exchange Offers and Consent Solicitations for its 7% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7 1/4% Senior Notes due 2022
PR Newswire Europe - Mon Apr 14, 7:02AM CDT
Endo International plc ("Endo" or the "Company" announced today that its wholly-owned subsidiary, Endo Health Solutions Inc. ("EHSI" , has amended the terms of its previously announced offers to exchange any and all of the outstanding unsecured 7% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7 1/4% Senior Notes due 2022 issued by EHSI (collectively, the "Existing EHSI Notes" , for new unsecured 7.00% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7.25% Senior Notes due 2022 (collectively, the "New Endo Finance Notes" , respectively, to be issued by Endo Finance LLC and Endo Finco Inc. (together, the "Endo Finance Issuers" and guaranteed by Endo Limited and certain of its direct and indirect subsidiaries, and the related solicitation of consents to amend the Existing EHSI Notes and the indentures governing the Existing EHSI Notes. Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Offer to Exchange (as defined below).
After Yesterday's Decline of 3.52%, Endo Pharmaceuticals Offers Investors Better Value
Comtex SmarTrend(R) - Fri Apr 11, 5:17PM CDT
Endo Pharmaceuticals (NASDAQ:ENDP) traded in a range yesterday that spanned from a low of $56.17 to a high of $60.21. Yesterday, the shares fell 3.5%, which took the trading range below the 3-day low of $58.50 on volume of 5.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Endo Health Solutions Inc. Announces Extension of Consent Date and Expiration Date in Exchange Offers and Consent Solicitations for its 7% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7-1/4% Senior Notes due 2022
PR Newswire Europe - Fri Apr 11, 7:02AM CDT
Endo International plc ("Endo" or the "Company" announced today that its wholly-owned subsidiary, Endo Health Solutions Inc. ("EHSI" , has further extended the consent date and expiration date in its previously announced offers to exchange any and all of the outstanding unsecured 7% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7A 1/4% Senior Notes due 2022 issued by EHSI (collectively, the "Existing EHSI Notes" , for new unsecured 7.00% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7.25% Senior Notes due 2022 (collectively, the "New Endo Finance Notes" , respectively, to be issued by Endo Finance LLC and Endo Finco Inc. (together, the "Endo Finance Issuers" and guaranteed by Endo Limited and certain of its direct and indirect subsidiaries (collectively, the "Guarantors" , and the related solicitation of consents to amend the Existing EHSI Notes and the indentures governing the Existing EHSI Notes. Capitalized terms used but not defined herein shall have the meanings ascribed to them in EHSI's Offer to Exchange dated March 27, 2014.
Federal Judge Enforces Settlement Agreement Between Mylan and Endo Regarding Generic FROVA®
PR Newswire - Fri Apr 11, 6:30AM CDT
Mylan Inc. (Nasdaq: MYL) today confirmed that a federal district court has granted its request to enforce a settlement agreement between Endo Pharmaceuticals and Mylan settling patent litigation in connection with Mylan's filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Frovatriptan Succinate Tablets, 2.5 mg. This product is the generic version of FROVA®, which is used to treat acute migraine headaches in adults.
Global Pain Management Therapeutics Market 2013-2019
M2 - Thu Apr 10, 8:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dqrj96/pain_management) has announced the addition of the "Global Pain Management Therapeutics Market 2013-2019" report to their offering. Impact of Patent Expiries Offset by Demand for Neuropathic and Rheumatoid Pain Medications and Strong Pipeline Global Pain Management Therapeutics Market 2013-2019 provides insights and analysis into the market. Pain is a widespread problem across the world. More than 25% of the total population suffers from some clinically significant pain in a year. Since pain considerably affects day-to-day activities in life, its management presents a considerable challenge for physicians. Inadequate pain control remains a major problem across the world. There is an urgent and unmet need to manage these pain-related problems accurately. Currently, the management of pain is not efficient due to low diagnosis and prescription rates. In many cases, such as cancer pain, 50% of the people taking medicines are not satisfied with the results. This is primarily due to the absence of a perfect pain management solution. Pain management can be most effective only when the underlying disease conditions are cured. However, there is no treatment that offers absolute relief for the indications covered in this report. The medications given for these indications are more for modifying the disease symptoms than offering complete relief from pain. The combination of under-managed pain, low awareness, and fear of addiction to some classes of pain medication is preventing people suffering pain from seeking treatment 100% of the time. Scope - Overview of the pain management market by analyzing the revenue, Annual Cost of Therapy (ACT) and treatment usage pattern across the top seven markets, which are the US, the UK, France, Germany, Spain, Italy and Japan. - Therapeutic landscape of the pain management therapeutics market and includes detailed market sizing and analysis of the trends in eight indications, which are fibromyalgia, neuropathic pain, cancer pain, Osteoarthritis (OA) pain, Rheumatoid Arthritis (RA) pain, migraine, Low Back Pain (LBP) and post-operative pain. - Geographical landscape of the pain management therapeutics market in the top seven markets, which are the US, the UK, France, Germany, Spain, Italy and Japan. - Detailed pipeline analysis of the pain management market (as of April 2013). The section also contains detailed analyses of the most promising pipeline molecules. - Profiles of the top companies operating in the pain management therapeutics market. - List of strategic consolidations, such as M&A deals, licensing agreements and partnership deals that took place in the global pain management therapeutics market between 2007 and 2013. Key Topics Covered: - Tables & Figures - Introduction - Market Overview - Therapeutic Landscape - Geographical Landscape - Asia-Pacific and China - Pipeline Analysis - Competitive Landscape - Strategic Consolidations - Management Therapeutics Market to 2019 - Appendix Companies Mentioned - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - Johnson & Johnson - Pfizer Inc - Purdue Pharma - Teva Pharmaceuticals (Cephalon, Inc.) For more information visit http://www.researchandmarkets.com/research/dq...management
Ampio Pharmaceuticals' Vyrix Enters into an Agreement with Paladin Labs for Exclusive Rights to Zertane(TM) in Canada and Other Territories to Broaden its International Footprint
PR Newswire - Thu Apr 10, 7:00AM CDT
Ampio Pharmaceuticals Inc. (NYSE MKT: AMPE) today announced that its wholly-owned subsidiary Vyrix Pharmaceuticals, a specialty pharmaceutical company focused on developing and commercializing late-stage prescription pharmaceuticals to improve men's sexual health, has signed an agreement with Paladin Labs Inc., a leading Canadian specialty pharmaceutical company, to provide exclusive rights to market, sell and distribute Zertane(TM) in Canada, the Republic of South Africa, Sub-Saharan Africa and Latin America.
Endo Health Solutions Inc. Announces Receipt of Requisite Tenders and Consents in the Exchange Offers and Consent Solicitations Relating to its 7% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7A 1/4% Senior Notes due 2022
PR Newswire Europe - Thu Apr 17, 7:01AM CDT
Endo International plc ("Endo" or the "Company"
announced today that its wholly-owned subsidiary, Endo Health Solutions Inc. ("EHSI" , has received requisite tenders and consents in connection with its previously announced offers to exchange any and all of the outstanding unsecured 7% Senior Notes due 2019 (the "2019 Existing EHSI Notes" , 7.00% Senior Notes due 2020 (the "2020 Existing EHSI Notes" and 7A 1/4% Senior Notes due 2022 issued by EHSI (the "2022 Existing EHSI Notes" and, together with the 2019 Existing EHSI Notes and the 2020 Existing EHSI Notes, the "Existing EHSI Notes" , for new unsecured 7.00% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7.25% Senior Notes due 2022 (collectively, the "New Endo Finance Notes" , respectively, to be issued by Endo Finance LLC and Endo Finco Inc. and guaranteed by Endo Limited and certain of its direct and indirect subsidiaries, and the related solicitation of consents to amend the Existing EHSI Notes and the indentures governing the Existing EHSI Notes. Consents were solicited in respect of the indentures governing each series of the Existing EHSI Notes to approve proposed amendments that would, among other things, (i) delete in their entirety substantially all the restrictive covenants in each indenture, (ii) modify the covenants regarding mergers and consolidations, and (iii) eliminate certain events of default. Capitalized terms used but not defined herein shall have the meanings ascribed to them in EHSI's Offer to Exchange dated March 27, 2014 (as amended from time to time, the "Offer to Exchange" . Endo Health Solutions Inc. Announces Receipt of Requisite Tenders and Consents in the Exchange Offers and Consent Solicitations Relating to its 7% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7¼% Senior Notes due 2022
PR Newswire - Thu Apr 17, 7:00AM CDT
Endo International plc (NASDAQ: ENDP) (TSX: ENL) ("Endo" or the "Company"
announced today that its wholly-owned subsidiary, Endo Health Solutions Inc. ("EHSI" , has received requisite tenders and consents in connection with its previously announced offers to exchange any and all of the outstanding unsecured 7% Senior Notes due 2019 (the "2019 Existing EHSI Notes" , 7.00% Senior Notes due 2020 (the "2020 Existing EHSI Notes" and 7¼% Senior Notes due 2022 issued by EHSI (the "2022 Existing EHSI Notes" and, together with the 2019 Existing EHSI Notes and the 2020 Existing EHSI Notes, the "Existing EHSI Notes" , for new unsecured 7.00% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7.25% Senior Notes due 2022 (collectively, the "New Endo Finance Notes" , respectively, to be issued by Endo Finance LLC and Endo Finco Inc. and guaranteed by Endo Limited and certain of its direct and indirect subsidiaries, and the related solicitation of consents to amend the Existing EHSI Notes and the indentures governing the Existing EHSI Notes. Consents were solicited in respect of the indentures governing each series of the Existing EHSI Notes to approve proposed amendments that would, among other things, (i) delete in their entirety substantially all the restrictive covenants in each indenture, (ii) modify the covenants regarding mergers and consolidations, and (iii) eliminate certain events of default. Capitalized terms used but not defined herein shall have the meanings ascribed to them in EHSI's Offer to Exchange dated March 27, 2014 (as amended from time to time, the "Offer to Exchange" . Noven Announces Settlement of Lidoderm(R) Patent Litigation
Business Wire - Wed Apr 16, 4:00PM CDT
Noven Pharmaceuticals, Inc. today announced that it has entered into an agreement with Endo Pharmaceuticals Inc., Teikoku Seiyaku Co., Ltd. and Teikoku Pharma USA, Inc. to settle all outstanding patent litigation related to Noven's lidocaine topical patch 5% product. An Abbreviated New Drug Application for Noven's product is currently pending at the U.S. Food and Drug Administration (FDA). If approved, Noven's product would be a generic version of Endo's Lidoderm(R).
Wednesday’s Top Health Care Stories: Zogenix, Endo, and Teva
Leo Sun, The Motley Fool - Motley Fool - Wed Apr 16, 8:21AM CDT
Let's take a quick look at three stocks -- Zogenix , Endo International , and Teva Pharmaceutical -- which could all loom large in health care headlines this morning. Zogenix surges after a U.S. court reverses the Massachusetts ban on...
Shares of ENDP Down 18.1% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Tue Apr 15, 5:04PM CDT
SmarTrend identified a Downtrend for Endo Pharmaceuticals (NASDAQ:ENDP) on March 24th, 2014 at $68.72. In approximately 3 weeks, Endo Pharmaceuticals has returned 18.10% as of today's recent price of $56.28.
Endo to Announce First Quarter 2014 Financial Results on May 1, 2014
PR Newswire Europe - Tue Apr 15, 3:01PM CDT
Endo International plc will announce its first quarter 2014 financial results before the open of the U.S. financial markets on May 1, 2014 and members of its senior management team will host a conference call and webcast at 7:30 a.m. ET that day.
Critical Alerts For Royal Dutch Shell, Keurig Green Mountain, Valspar, Lorillard, and Endo Pharmaceuticals Released By InvestorsObserver
PR Newswire - Tue Apr 15, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for RDS.A, GMCR, VAL, LO, and ENDP.
Legal Updates, Stock Price Movements, New Awareness Campaigns, and Senior-level Appointments - Analyst Notes on Mylan, WellPoint, Forest, Novatis and Intercept
PR Newswire - Tue Apr 15, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Mylan Inc. (NASDAQ: MYL), WellPoint Inc. (NYSE: WLP), Forest Laboratories Inc. (NYSE: FRX), Novatis AG (NYSE: NVS) and Intercept Pharmaceuticals Inc. (NASDAQ: ICPT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1162-100free.
Endo International (ENDP) Shares Cross Below 200 DMA
at The Street - Mon Apr 14, 3:42PM CDT
In trading on Monday, shares of Endo International plc Ord crossed below their 200 day moving average of $55.95, changing hands as low as $55.85 per share. Endo International plc Ord shares are currently trading off about 1% on the day.
Mylan to Settle with Endo on Frova - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 14, 10:40AM CDT
A federal district court granted Mylan's request to forge a settlement with Endo regarding Frova.
Mylan announces favourable settlement agreement with Endo Pharmaceuticals for Frovatriptan Succinate Tablets, 2.5 mg
M2 - Mon Apr 14, 9:05AM CDT
Pharmaceutical company Mylan (NasdaqGS:MYL) said on Friday that the federal district court has granted its request to enforce a settlement agreement with Endo Pharmaceuticals for Frovatriptan Succinate Tablets, 2.5 mg.
Endo Health Solutions Inc. Amends Exchange Offers and Consent Solicitations for its 7% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7 1/4% Senior Notes due 2022
PR Newswire Europe - Mon Apr 14, 7:02AM CDT
Endo International plc ("Endo" or the "Company"
announced today that its wholly-owned subsidiary, Endo Health Solutions Inc. ("EHSI" , has amended the terms of its previously announced offers to exchange any and all of the outstanding unsecured 7% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7 1/4% Senior Notes due 2022 issued by EHSI (collectively, the "Existing EHSI Notes" , for new unsecured 7.00% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7.25% Senior Notes due 2022 (collectively, the "New Endo Finance Notes" , respectively, to be issued by Endo Finance LLC and Endo Finco Inc. (together, the "Endo Finance Issuers" and guaranteed by Endo Limited and certain of its direct and indirect subsidiaries, and the related solicitation of consents to amend the Existing EHSI Notes and the indentures governing the Existing EHSI Notes. Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Offer to Exchange (as defined below). After Yesterday's Decline of 3.52%, Endo Pharmaceuticals Offers Investors Better Value
Comtex SmarTrend(R) - Fri Apr 11, 5:17PM CDT
Endo Pharmaceuticals (NASDAQ:ENDP) traded in a range yesterday that spanned from a low of $56.17 to a high of $60.21. Yesterday, the shares fell 3.5%, which took the trading range below the 3-day low of $58.50 on volume of 5.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Endo Health Solutions Inc. Announces Extension of Consent Date and Expiration Date in Exchange Offers and Consent Solicitations for its 7% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7-1/4% Senior Notes due 2022
PR Newswire Europe - Fri Apr 11, 7:02AM CDT
Endo International plc ("Endo" or the "Company"
announced today that its wholly-owned subsidiary, Endo Health Solutions Inc. ("EHSI" , has further extended the consent date and expiration date in its previously announced offers to exchange any and all of the outstanding unsecured 7% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7A 1/4% Senior Notes due 2022 issued by EHSI (collectively, the "Existing EHSI Notes" , for new unsecured 7.00% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7.25% Senior Notes due 2022 (collectively, the "New Endo Finance Notes" , respectively, to be issued by Endo Finance LLC and Endo Finco Inc. (together, the "Endo Finance Issuers" and guaranteed by Endo Limited and certain of its direct and indirect subsidiaries (collectively, the "Guarantors" , and the related solicitation of consents to amend the Existing EHSI Notes and the indentures governing the Existing EHSI Notes. Capitalized terms used but not defined herein shall have the meanings ascribed to them in EHSI's Offer to Exchange dated March 27, 2014. Federal Judge Enforces Settlement Agreement Between Mylan and Endo Regarding Generic FROVA®
PR Newswire - Fri Apr 11, 6:30AM CDT
Mylan Inc. (Nasdaq: MYL) today confirmed that a federal district court has granted its request to enforce a settlement agreement between Endo Pharmaceuticals and Mylan settling patent litigation in connection with Mylan's filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Frovatriptan Succinate Tablets, 2.5 mg. This product is the generic version of FROVA®, which is used to treat acute migraine headaches in adults.
Global Pain Management Therapeutics Market 2013-2019
M2 - Thu Apr 10, 8:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dqrj96/pain_management) has announced the addition of the "Global Pain Management Therapeutics Market 2013-2019" report to their offering. Impact of Patent Expiries Offset by Demand for Neuropathic and Rheumatoid Pain Medications and Strong Pipeline Global Pain Management Therapeutics Market 2013-2019 provides insights and analysis into the market. Pain is a widespread problem across the world. More than 25% of the total population suffers from some clinically significant pain in a year. Since pain considerably affects day-to-day activities in life, its management presents a considerable challenge for physicians. Inadequate pain control remains a major problem across the world. There is an urgent and unmet need to manage these pain-related problems accurately. Currently, the management of pain is not efficient due to low diagnosis and prescription rates. In many cases, such as cancer pain, 50% of the people taking medicines are not satisfied with the results. This is primarily due to the absence of a perfect pain management solution. Pain management can be most effective only when the underlying disease conditions are cured. However, there is no treatment that offers absolute relief for the indications covered in this report. The medications given for these indications are more for modifying the disease symptoms than offering complete relief from pain. The combination of under-managed pain, low awareness, and fear of addiction to some classes of pain medication is preventing people suffering pain from seeking treatment 100% of the time. Scope - Overview of the pain management market by analyzing the revenue, Annual Cost of Therapy (ACT) and treatment usage pattern across the top seven markets, which are the US, the UK, France, Germany, Spain, Italy and Japan. - Therapeutic landscape of the pain management therapeutics market and includes detailed market sizing and analysis of the trends in eight indications, which are fibromyalgia, neuropathic pain, cancer pain, Osteoarthritis (OA) pain, Rheumatoid Arthritis (RA) pain, migraine, Low Back Pain (LBP) and post-operative pain. - Geographical landscape of the pain management therapeutics market in the top seven markets, which are the US, the UK, France, Germany, Spain, Italy and Japan. - Detailed pipeline analysis of the pain management market (as of April 2013). The section also contains detailed analyses of the most promising pipeline molecules. - Profiles of the top companies operating in the pain management therapeutics market. - List of strategic consolidations, such as M&A deals, licensing agreements and partnership deals that took place in the global pain management therapeutics market between 2007 and 2013. Key Topics Covered: - Tables & Figures - Introduction - Market Overview - Therapeutic Landscape - Geographical Landscape - Asia-Pacific and China - Pipeline Analysis - Competitive Landscape - Strategic Consolidations - Management Therapeutics Market to 2019 - Appendix Companies Mentioned - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - Johnson & Johnson - Pfizer Inc - Purdue Pharma - Teva Pharmaceuticals (Cephalon, Inc.) For more information visit http://www.researchandmarkets.com/research/dq...management
Ampio Pharmaceuticals' Vyrix Enters into an Agreement with Paladin Labs for Exclusive Rights to Zertane(TM) in Canada and Other Territories to Broaden its International Footprint
PR Newswire - Thu Apr 10, 7:00AM CDT
Ampio Pharmaceuticals Inc. (NYSE MKT: AMPE) today announced that its wholly-owned subsidiary Vyrix Pharmaceuticals, a specialty pharmaceutical company focused on developing and commercializing late-stage prescription pharmaceuticals to improve men's sexual health, has signed an agreement with Paladin Labs Inc., a leading Canadian specialty pharmaceutical company, to provide exclusive rights to market, sell and distribute Zertane(TM) in Canada, the Republic of South Africa, Sub-Saharan Africa and Latin America.
